Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

Mise à jour : Il y a 4 ans
Référence : NCT00713310

Femme et Homme

Extrait

The overall objective of this study is to assess the safety and efficacy of high dose and low dose Asacol administered as 400 mg delayed-release tablets given every 12 hours for 6 weeks to children and adolescents with mildly-to-moderately active ulcerative colitis.


Critère d'inclusion

  • Ulcerative colitis


Liens